Drugs / Plasminogen (Human)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02312180 | Dec 2014 → Dec 2015 | hypoplasminogenemia | Prometic Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03265171 | — | hypoplasminogenemia | Prometic Biotherapeutics, Inc. | No longer available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plasminogen (Human) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03265171 ↗ |
| Known as | ProMetic Plasminogen | “ProMetic is intiitating a first-in-man study entitled "A Phase 1, Dose Escalation, and Pharmacokinetic Study of ProMetic Plasminogen Administered as Intravenous Infusion in...” NCT02312180 ↗ |
| Modality | Protein / enzyme biologic | “Plasma-derived purified plasminogen formulated for intravenous administration” NCT02312180 ↗ |
| Route | Intravenous | “Plasminogen will be administered as an intravenous (IV) infusion at the following doses:” NCT02312180 ↗ |